|
1
|
Ismailov RM: Global heart failure rates
and erythropoietin. Iran J Med Hypotheses Ideas. 6:70–74. 2012.
View Article : Google Scholar
|
|
2
|
Zhang XJ, Liu J, Wan L, Sun Y, Wang F, Qi
YJ and Huang CB: Relations of synovial angiogenesis and
PTEN/PI3K/AKT signaling pathway in rats with adjuvant arthritis.
Zhongguo Gu Shang. 28:71–74. 2015.(In Chinese). PubMed/NCBI
|
|
3
|
Polat N, Oz F, Baykız D, Cizgici AY, Altun
I, Buğra Z, Umman B, Tufan F and Oflaz H: Predictors of functional
capacity in younger and elderly chronic heart failure patients: An
observational study. Anadolu Kardiyol Derg. 13:778–783.
2013.PubMed/NCBI
|
|
4
|
Iwanami J, Mogi M, Iwai M and Horiuchi M:
Inhibition of the renin-angiotensin system and target organ
protection. Hypertens Res. 32:229–237. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Suzuki N, Mukai HY and Yamamoto M: In vivo
regulation of erythropoiesis by chemically inducible dimerization
of the erythropoietin receptor intracellular domain. PLoS One.
10:e01194422015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wan LJ and Wu XH: Effects of
erythropoietin on cardiomyocyte apoptosis and endoplasmic reticulum
stress-related proteins in neonatal rats with asphyxia. Zhongguo
Dang Dai Er Ke Za Zhi. 15:890–895. 2013.(In Chinese). PubMed/NCBI
|
|
7
|
Chang ZY, Yeh MK, Chiang CH, Chen YH and
Lu DW: Erythropoietin protects adult retinal ganglion cells against
NMDA-, trophic factor withdrawal-, and TNF-α-induced damage. PLoS
One. 8:e552912013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Doue T, Ohtsuki K, Ogawa K, Ueda M, Azuma
A, Saji H, Strauss HW and Matsubara H: Cardioprotective effects of
erythropoietin in rats subjected to ischemia-reperfusion injury:
Assessment of infarct size with 99mTc-annexin V. J Nucl Med.
49:1694–1700. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wen Y, Xu J, Ma X and Gao Q: High-dose
erythropoietin in acute ST-segment elevation myocardial infarction:
A meta-analysis of randomized controlled trials. Am J Cardiovasc
Drugs. 13:435–442. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Minamino T, Toba K, Higo S, Nakatani D,
Hikoso S, Umegaki M, Yamamoto K, Sawa Y, Aizawa Y and Komuro I;
EPO-AMI-II study investigators, . Design and rationale of low-dose
erythropoietin in patients with ST-segment elevation myocardial
infarction (EPO-AMI-II study): A randomized controlled clinical
trial. Cardiovasc Drugs Ther. 26:409–416. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fiordaliso F, Chimenti S, Staszewsky L,
Bai A, Carlo E, Cuccovillo I, Doni M, Mengozzi M, Tonelli R, Ghezzi
P, et al: A nonerythropoietic derivative of erythropoietin protects
the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci
USA. 102:2046–2051. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kretz A, Happold CJ, Marticke JK and
Isenmann S: Erythropoietin promotes regeneration of adult CNS
neurons via Jak2/Stat3 and PI3K/AKT pathway activation. Mol Cell
Neurosci. 29:569–579. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lu X, Lv S, Mi Y, Wang L and Wang G:
Neuroprotective effect of miR-665 against sevoflurane
anesthesia-induced cognitive dysfunction in rats through PI3K/Akt
signaling pathway by targeting insulin-like growth factor 2. Am J
Transl Res. 9:1344–1356. 2017.PubMed/NCBI
|
|
14
|
Gasparotto EPL, Tognon R, Ferreira AF,
Oliveira GLV, Palma PVB, Zanichelli MA, Souto EX, Velano CEE,
Carrara RCV, Kashima S, et al: Deregulated expression of A1,
Bcl-2, Bcl-xL, and Mcl-1 antiapoptotic proteins and Bid,
Bad, and Bax proapoptotic genes in polycythemia vera patients. Braz
J Pharm Sci. 47:873–886. 2011. View Article : Google Scholar
|
|
15
|
Sattarzadeh R, Tavoosi A and Tajik P:
Echocardiographic estimation of left ventricular filling pressures
in patients with mitral valve stenosis. Cardiovasc J Afr. 25:34–39.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li Y, Takemura G, Okada H, Miyata S,
Maruyama R, Li L, Higuchi M, Minatoguchi S, Fujiwara T and Fujiwara
H: Reduction of inflammatory cytokine expression and oxidative
damage by erythropoietin in chronic heart failure. Cardiovasc Res.
71:684–694. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Martins QC, Aliti G and Rabelo ER:
Decreased cardiac output: Clinical validation in patients with
decompensated heart failure. Int J Nurs Terminol Classif.
21:156–165. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu W, Shen Y, Plane JM, Pleasure DE and
Deng W: Neuroprotective potential of erythropoietin and its
derivative carbamylated erythropoietin in periventricular
leukomalacia. Exp Neurol. 230:227–239. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Millet A, Bouzat P, Trouve-Buisson T,
Batandier C, Pernet-Gallay K, Gaide-Chevronnay L, Barbier EL,
Debillon T, Fontaine E and Payen JF: Erythropoietin and its
derivates modulate mitochondrial dysfunction after diffuse
traumatic brain injury. J Neurotrauma. 33:1625–1633. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li X, Bai ZY, Zhang FY and Xu XY:
Neuroprotection of herbs promoting EPO on cerebral ischemia.
Zhongguo Zhong Yao Za Zhi. 40:2265–2271. 2015.(In Chinese).
PubMed/NCBI
|
|
21
|
Gu YX, Du J, Si MS, Mo JJ, Qiao SC and Lai
HC: The roles of PI3K/Akt signaling pathway in regulating MC3T3-E1
preosteoblast proliferation and differentiation on SLA and SLActive
titanium surfaces. J Biomed Mater Res A. 101:748–754. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Stewart JT, Grbic M and Sigwart U: Left
atrial and left ventricular diastolic function during acute
myocardial ischaemia. Br Heart J. 68:377–381. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He H, Qiao X and Wu S: Carbamylated
erythropoietin attenuates cardiomyopathy via PI3K/Akt activation in
rats with diabetic cardiomyopathy. Exp Ther Med. 6:567–573. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ueba H, Brines M, Yamin M, Umemoto T, Ako
J, Momomura S, Cerami A and Kawakami M: Cardioprotection by a
nonerythropoietic, tissue-protective peptide mimicking the 3D
structure of erythropoietin. Proc Natl Acad Sci USA.
107:14357–14362. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen Q, Xu T, Li D, Pan D, Wu P, Luo Y, Ma
Y and Liu Y: JNK/PI3K/Akt signaling pathway is involved in
myocardial ischemia/reperfusion injury in diabetic rats: effects of
salvianolic acid A intervention. Am J Transl Res. 8:2534–2548.
2016.PubMed/NCBI
|
|
26
|
de Oliveira MR, Ferreira GC, Schuck PF and
Dal Bosco SM: Role for the PI3K/Akt/Nrf2 signaling pathway in the
protective effects of carnosic acid against methylglyoxal-induced
neurotoxicity in SH-SY5Y neuroblastoma cells. Chem Biol Interact.
242:396–406. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang N, Li T and Han P: The effect of
tianmai xiaoke pian on insulin resistance through PI3-K/AKT
signal pathway. J Diabetes Res. 2016:92612592016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cen L, Hsieh FC, Lin HJ, Chen CS, Qualman
SJ and Lin J: PDK-1/AKT pathway as a novel therapeutic target in
rhabdomyosarcoma cells using OSU-03012 compound. Br J Cancer.
97:785–791. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wei X, Wang G, Li W, Hu X, Huang Q, Xu K,
Lou W, Wu J, Liang C, Lou Q, et al: Activation of the JAK-STAT3
pathway is associated with the growth of colorectal carcinoma
cells. Oncol Rep. 31:335–341. 2014. View Article : Google Scholar : PubMed/NCBI
|
